"Based on the positive randomized Phase 2 data and a Phase 3 plan we believe is designed for ... Agreement on the Phase 3 ...

Research and development expenses increased to $17.0 million for the three months ended September 30, 2024 from $15.4 million for the three months ended September 30, 2023 primarily due to ...

In this age of AI, enterprises need to be able to quickly access and extract value from edge data. Here's how Dell is helping them do it.

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Secondly, a longitudinal analysis of HCV patients showed 80% of patients ... which include additional safety and resistance data for bemnifosbuvir and modeling data on the lead-in cohort from the ...

Greetings, and welcome to the Moleculin Biotech Quarterly Update Conference Call and Webcast. At this time, all participants are in listen only mode. [Operator Instructions] A question-and-answer ...

EBR Systems is among ASX healthcare stocks with upcoming catalysts, expecting feedback on a FDA substantive review expected ...

Finance leaders who can effectively harness the power of data are better positioned to meet today’s challenges and drive ...

Women’s sports is finally prioritizing performance data collection and analysis needed to enhance training regimens for ...

Operator: Ladies and gentlemen, welcome to Cassava Sciences Report for the Third Quarter 2024. At this time, all participants are in a listen-only mode.

Provide specific products and services to you, such as portfolio management or data aggregation. Develop and improve features ... the unvarnished thinking of our people and exacting analysis of our ...